BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...

Overview: Mircera is used to treat anemia. Common side effects include diarrhea and pain or swelling in the nose or throat. Serious side effects are rare but include blood clots, seizures, and severe ...

(4) For patients not currently treated with an erythropoiesis stimulating agent (ESA), the recommended starting dose is 0.6 microgram/kg body weight, administered once every two weeks as a single ...

being a common adverse event and a burden for patients with chronic kidney disease (CKD).

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

NUTLEY, N.J., Nov. 14 Roche announced today that the U.S. Food and Drug Administration (FDA) has approved MIRCERA (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia associated with ...

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA® and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...